Evidence map›Paper›PMID 34352044›Full record

ArticlePLoS pathogens2021

EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.

Chenhe Su, Fang Lu, Samantha S Soldan, R Jason Lamontagne, Hsin-Yao Tang, Giorgia Napoletani, Paul J Farrell, Italo Tempera, Andrew V Kossenkov, Paul M Lieberman

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Is DEXI a Multiple Sclerosis Susceptibility Gene?International journal of molecular sciences · 2025
    Review
  10. Review
  11. Viral remodeling of the 4D nucleome.Experimental & molecular medicine · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Protein Posttranslational Signatures Identified in COVID-19 Patient Plasma.Frontiers in cell and developmental biology · 2022
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Chenhe SuThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Fang LuThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Samantha S SoldanThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-6263-519X
R Jason LamontagneThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-9068-3348
Hsin-Yao TangThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0003-1838-018X
Giorgia NapoletaniThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Paul J FarrellImperial College, London, United Kingdom.ORCID 0000-0002-6754-9351
Italo TemperaThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-7893-2914
Andrew V KossenkovThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Paul M LiebermanThe Wistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-3935-9921
The Wistar Institute · USImperial College London · GB

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Regulation of Epstein-Barr Virus LatencyR01CA093606 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2002 to 2022
$6.7M
Epigenetic Regulation of Epstein-Barr Virus Latency ProgramsR01DE017336 · NIDCR · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2005 to 2026
$6.5M
Regulation of Viral Chromatin Architecture During EBV LatencyR01AI130209 · NIAID · WISTAR INSTITUTE · PI Italo Tempera · 2018 to 2026
$3.8M
Regulation of EBV Latency by Purine Metabolism and SignalingR01AI153508 · NIAID · WISTAR INSTITUTE · PI TEMPERA, ITALO · 2021 to 2025
$2.3M
Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6M
Medical Research Council MR/S0022597/1Medical Research Council MR/S022597/1NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA093606NCI NIH HHS R50 CA211199NCI NIH HHS R50 CA221838NIAID NIH HHS R01 AI130209NIAID NIH HHS R01 AI153508NIDCR NIH HHS R01 DE017336
6 · The paper itself

Abstract

Viruses suppress immune recognition through diverse mechanisms. Epstein-Barr Virus (EBV) establishes latent infection in memory B-lymphocytes and B-cell malignancies where it impacts B-cell immune function. We show here that EBV primary infection of naïve B-cells results in a robust down-regulation of HLA genes. We found that the viral encoded transcriptional regulatory factor EBNA2 bound to multiple regulatory regions in the HLA locus. Conditional expression of EBNA2 correlated with the down regulation of HLA class II transcription. EBNA2 down-regulation of HLA transcription was found to be dependent on CIITA, the major transcriptional activator of HLA class II gene transcription. We identified a major EBNA2 binding site downstream of the CIITA gene and upstream of DEXI, a dexamethasone inducible gene that is oriented head-to-head with CIITA gene transcripts. CRISPR/Cas9 deletion of the EBNA2 site upstream of DEXI attenuated CIITA transcriptional repression. EBNA2 caused an increase in DEXI transcription and a graded change in histone modifications with activation mark H3K27ac near the DEXI locus, and a loss of activation marks at the CIITA locus. A prominent CTCF binding site between CIITA and DEXI enhancers was mutated and further diminished the effects of EBNA2 on CIITA. Analysis of HiC data indicate that DEXI and CIITA enhancers are situated in different chromosome topological associated domains (TADs). These findings suggest that EBNA2 down regulates HLA-II genes through the down regulation of CIITA, and that this down regulation is an indirect consequence of EBNA2 enhancer formation at a neighboring TAD. We propose that enhancer competition between these neighboring chromosome domains represents a novel mechanism for gene regulation demonstrated by EBNA2.

Indexed as

Enhancer Elements, GeneticB-LymphocytesDNA-Binding ProteinsEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensGene Expression RegulationGenes, MHC Class IIHerpesvirus 4, HumanHumansMembrane ProteinsNuclear ProteinsPromoter Regions, GeneticTrans-ActivatorsViral ProteinsDEXI protein, humanDNA-Binding ProteinsEBNA-2 protein, Human herpesvirus 4Epstein-Barr Virus Nuclear AntigensMembrane ProteinsMHC class II transactivator proteinNuclear ProteinsTrans-ActivatorsViral Proteins

Identifiers

PMID34352044
PMCPMC8370649
OpenAlexW3188651380

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.